








Supplementary Figure 1






Supplementary Figure 2














A**SKM-1, 6 days****QA-68****EA-89****Supplementary Figure 3(A)**

B


















Supplementary Figure 5


A

D

B

E

C

F


Supplementary Figure 6 (A-D)


A**B****C****D**




Supplementary Figure 6 (E-L)





Supplementary Figure 7



Supplementary Figure 8




Supplementary Figure 10





SKM-1

		Treatment	CD11b
		DMSO	38.7
		QA68 (0.1 nM)	45.8
		decitabine (25 nM)	64.4
Drug Combination	➔	QA68 (0.1 nM)+decitabine (25 nM)	73.4
		DMSO	38.7
		QA68 (0.1 nM)	45.8
		5-azacytidine (25 nM)	43.8
Drug Combination	➔	QA68 (0.1 nM)+5-azacytidine (25 nM)	55.1
		DMSO	38.7
		QA68 (1 nM)	84.5
		venetoclax (625 nM)	83.6
Drug Combination	➔	QA68 (1 nM)+venetoclax (625 nM)	97.1
		DMSO	38.7
		EA89 (1000 nM)	65.7
		decitabine (25 nM)	64.4
Drug Combination	➔	EA89 (1000 nM)+decitabine (25 nM)	83.4
		DMSO	38.7
		EA89 (1000 nM)	65.7
		5-azacytidine (25 nM)	43.8
Drug Combination	➔	EA89 (1000 nM)+5-azacytidine (25 nM)	61.1
		DMSO	38.7
		EA89 (1000 nM)	65.7
		venetoclax (625 nM)	83.6
Drug Combination	➔	EA89 (1000 nM)+venetoclax (625 nM)	92.9




Supplementary Figure 11


A *MV411, Comparison of UP & DOWN reg DEGS between degraders*



B *MV411, dBRD9-A vs DMSO*



Supplementary Figure 12 (A-C)

D**E**